Apellis announces 5-year GALE data showing SYFOVRE delayed progression of GA

Apellis (APLS) Pharmaceuticals announced data from a post hoc analysis of the GALE extension study following five years of continuous treatment with SYFOVRE, the leading treatment for geographic atrophy, GA, secondary to age-related macular degeneration, AMD. The results demonstrate that both every-other-month and monthly SYFOVRE delayed GA lesion growth by approximately 1.5 years in patients with nonsubfoveal GA when compared to sham/projected sham. “I’m very encouraged by these long-term results, which show that early and continuous treatment with SYFOVRE can meaningfully delay the progression of GA,” said Dilsher Dhoot, M.D., California Retina Consultants. “Importantly, these data indicate that SYFOVRE alters the natural course of this disease, which causes irreversible vision loss and profoundly impacts patients’ daily lives.”